NHS Approves Two Treatments for Children With Spinal Muscular Atrophy

1-Minute Brief

The decision enables wider access to therapies for a rare muscle-wasting disease, following advocacy from affected families.

Key Facts

• Hundreds of children with spinal muscular atrophy (SMA) will be able to access two approved drugs.
• The National Institute for Health and Care Excellence (Nice) published final draft guidance recommending the treatments.
• Jesy Nelson campaigned for expanded screening after her twins were diagnosed with SMA.
• Parents described the approval as a 'lifeline' for affected children.
• The treatments are intended for any patient who would benefit, according to the guidance.

What Happened

The NHS will offer two newly approved treatments for spinal muscular atrophy to hundreds of children, following final draft guidance from Nice and advocacy efforts.

Why It Matters

This move may improve survival and quality of life for children with SMA, a rare and serious condition, and reflects the impact of patient and family advocacy on healthcare policy.

What's Next

Eligible patients are expected to gain access to the drugs under NHS care. Further updates may follow as the implementation progresses.